PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing innovative RNA therapies for genetic diseases. The company leverages a proprietary drug delivery platform to enhance the precision and effectiveness of RNA-based treatments, targeting conditions with limited or no existing therapies. Its pipeline includes programs for rare monogenic disorders such as Retinitis Pigmentosa, Polycystic Kidney Disease, Autosomal Dominant Optic Atrophy, and Phelan-McDermid Syndrome. Headquartered in Perth, Australia, PYC Therapeutics operates exclusively within the healthcare sector and is recognized for its scientific rigor and commitment to advancing novel therapeutics. The company is listed on the CHI-X Market Australia - Limit Venue, providing investors access to its shares through this alternative trading platform. PYC Therapeutics is classified as a defensive stock within the biotechnology industry, reflecting its research-driven business model and potential for long-term impact in the field of genetic medicine.